Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

68 results about "Toll" patented technology

The toll genes encode members of the toll-like receptor class of proteins. Mutants in the toll gene were originally identified by 1995 Nobel Laureates Christiane Nüsslein-Volhard and Eric Wieschaus and colleagues in the fruit fly Drosophila melanogaster in 1985, and cloned by the laboratory of Kathryn Anderson in 1988. Since then, thirteen mammalian toll genes have been identified. In flies, toll was first identified as a gene important in embryogenesis in establishing the dorsal-ventral axis. In 1996, toll was found to have a role in the fly's immunity to fungal infections. Both mammalian and invertebrate toll genes are required for innate immunity. Toll-like receptors in mammals were identified in 1997 at Yale University by Ruslan Medzhitov and Charles Janeway. Concurrently, two separate studies, led by Shizuo Akira, Bruce A. Beutler and their respective colleagues discovered that the Toll-like receptors act as the principal sensors of infection in mammals. The name of the gene family derives from Christiane Nüsslein-Volhard's 1985 exclamation, "Das ist ja toll!" The exclamation, which translates as "That's amazing!"

Polypeptides and use thereof

An isolated polypeptide comprises an amino acid sequence of SEQ ID No. 1 or 2 or a variant or fragment thereof. The variant may comprise an amino acid sequence that is at least 70% or 95% identical to the amino acid sequence of SEQ ID No. 1 or 2. A fragment thereof may be a peptide comprising at least 12 contiguous amino acids of SEQ ID No. 1 or 2. The polypeptide exhibits toll-like receptor activity. The TLR has been named TLR1 4. TLR receptors recognise a range of ligands and activate a series of signalling pathways that lead to the induction of immune and inflammatory genes.
Owner:OPSONA THERAPEUTICS

TLR (Toll-like receptor) modulators, pharmaceutical composition thereof, preparation method and application

The invention belongs to the field of pharmaceutical chemistry, particularly relates to compounds with TLR (Toll-like receptor) modulation effect as well as a preparation method and an application ofthe compounds, and provides compounds represented by the following formula X in the description. The compounds of formula X can be used as the TLR modulators and have higher activity. Besides, the compounds have the characteristics of high efficiency, low toxicity, resistance to drug resistance and the like, and have clinical application value. Moreover, synthesis steps of the compounds are simple, so that the compounds have higher economic utilization value.
Owner:北京施安泰医药技术开发有限公司

Methods of Treating, Reducing, or Preventing Autoimmune Conditions

The present invention relates to methods and kits for treating, reducing, or preventing autoimmune conditions such as rheumatoid arthritis by administering to a mammal in need thereof an agent that modulates the expression level or biological activity of Toll-like receptor-9 (TLR-9). Also disclosed are screening methods that make use of TLR-9 for the identification of novel therapeutics for autoimmune conditions.
Owner:JOSLIN D ABETES CENTER INC

Method to identify polypeptide toll-like receptor (TLR) ligands

The present invention provides novel methods to identify polypeptide ligands for Toll-like Receptors (TLRs), such as TLR2, TLR4 and TLR5. The method involves the use of phage display technology in an iterative biopanning procedure. The invention also provides polypeptide TLR ligands identified by the methods of the invention. In preferred embodiments, the polypeptide TLR ligands so identified modulate TLR signaling and thereby regulate the Innate Immune Response. The invention also provides vaccines comprising a polypeptide TLR ligand identified by the methods of the invention and an antigen. The invention also provides methods of modulating TLR signaling using the polypeptide TLR ligands and vaccines of the invention.
Owner:VAXINNATE

Anti-tlr4 antibodies and methods of use thereof

This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and / or prolonging survival of transplanted biological material.
Owner:NOVIMMUNE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products